



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
Main Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2011

---

**Transapical aortic implantation of autologous marrow stromal cell-based tissue-engineered heart valves: first experiences in the systemic circulation**

Emmert, M Y ; Weber, B ; Behr, L ; Frauenfelder, T ; Brokopp, C E ; Grünenfelder, J ; Falk, V ;  
Hoerstrup, S P

DOI: <https://doi.org/10.1016/j.jcin.2011.02.020>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-50829>

Journal Article

Accepted Version

Originally published at:

Emmert, M Y; Weber, B; Behr, L; Frauenfelder, T; Brokopp, C E; Grünenfelder, J; Falk, V; Hoerstrup, S P (2011). Transapical aortic implantation of autologous marrow stromal cell-based tissue-engineered heart valves: first experiences in the systemic circulation. *JACC: Cardiovascular Interventions*, 4(7):822-823.

DOI: <https://doi.org/10.1016/j.jcin.2011.02.020>

# Transapical Aortic Implantation of Autologous Marrow Stromal Cell-Based Tissue-Engineered Heart Valves: First Experiences in the Systemic Circulation

Maximilian Y. Emmert MD<sup>1,2,3</sup>, Benedikt Weber MD<sup>1,2,3</sup>, Luc Behr VDM, PhD<sup>5</sup>, Thomas Frauenfelder MD<sup>4</sup>, Chad E. Brokopp MSc<sup>1,3</sup>, Jürg Grünenfelder MD<sup>2</sup>, Volkmar Falk MD<sup>2</sup>, Simon P. Hoerstrup MD, PhD<sup>1,2,3</sup>

<sup>1</sup> Department of Surgical Research, University Hospital of Zurich, Zurich, Switzerland

<sup>4</sup> Department of Radiology, University Hospital of Zurich, Zurich, Switzerland

<sup>2</sup> Clinic for Cardiovascular Surgery, University Hospital of Zurich, Zurich, Switzerland

<sup>3</sup> Swiss Center for Regenerative Medicine, Zurich, Switzerland

<sup>5</sup> IMM RECHERCHE, Institut Mutualiste Montsouris, Paris, France

Within 1 procedure, tissue-engineered, living heart valves (TEHVs), fabricated from biodegradable scaffolds seeded with autologous bone marrow-derived mononuclear cells (Fig. 1A), were integrated into self-expanding nitinol stents (20 mm × 30 mm) and transapically delivered into the descending aorta (n = 2) (distal to the brachiocephalic trunk) and the brachiocephalic trunk (n = 1) of sheep (Fig. 1A). Native valve incompetence was created by applying the Hufnagel procedure (1) before implantation (Fig. 1A). After successful deployment (Figs. 1B and 1C), valve function and optimal positioning were confirmed using fluoroscopy (Fig. 1B, Online Video 1), computed tomography (CT) (Figs. 1D and 1E, Online Video 2), and echocardiography (Figs. 1F to 1M, Online Videos 3A, 3B, and 3C). The crimping time of the TEHVs was  $15 \pm 2$  min. The overall duration of the procedure, from the preparation of cells to the successful delivery, was 2 h. Post-mortem analysis displayed fully intact TEHVs and, in particular, well-defined leaflets showing coaptation. There were no signs of leaflet rupture, microstructure damage, or thrombus formation detectable.

So far, successful TEHV implantations have only been reported for low-pressure systems such as in the pulmonary position (2), and clinical trials have been initiated. This is the first report demonstrating the feasibility of the minimally invasive, catheter-assisted implantation of TEHV into the systemic circulation with adequate valvular functionality in an acute study based on an easily accessible, clinically relevant cell source (3) and minimally invasive

techniques for both cell harvest and delivery (2) within 1 procedure. Such autologous and living heart valves may hold potential to overcome the limitations of the currently used bioprosthetic valves inherently prone to calcification and progressive dysfunctional degeneration. This may broaden the future clinical application of transcatheter valves beyond elderly high-risk patients.


## References

A.R. Cale, C.T. Sang, C. Campanella and E.W. Cameron, Hufnagel-revisited: a descending thoracic aortic valve to treat prosthetic valve insufficiency. *Ann Thorac Surg*, 55 (1993), pp. 1218–1221.

2 D. Schmidt, P.E. Dijkman and A. Driessen-Mol, *et al.* Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. *J Am Coll Cardiol*, 56 (2010), pp. 510–520.

3 T. Shin'oka, Y. Imai and Y. Ikada, Transplantation of a tissue-engineered pulmonary artery. *N Engl J Med*, 344 (2001), pp. 532–533.

The authors have reported that they have no relationships to disclose. Drs. Emmert and Weber contributed equally to this work.



**Figure 1:** Tissue-Engineered Heart Valves

(A) Tissue-engineered heart valves (TEHVs) (inset) were transapically delivered into the descending aorta (distal to the brachiocephalic trunk) and into the brachiocephalic trunk of adult sheep after creating native valve insufficiency by applying the Hufnagel procedure. (B) Contrast angiography displayed optimal positioning and normal function of the TEHV. (C) Post-mortem analysis confirmed positioning in the descending aorta distal to the brachiocephalic trunk. (D and E) Three-dimensional (3D) computed tomography reconstruction of the adult sheep heart (D and E showing anterior view, inset showing posterior view) with the self-expanding nitinol stent positioned in the descending aorta (‡) distal to the brachiocephalic trunk (\*). (F to M) Transesophageal echocardiography (TEE) in the 2-dimensional (2D); (G and H), 2D color (I), and 3D (J to M) modes displayed the TEHV in the descending aorta (‡) above the native valve (\*). In particular, the TEE analysis showed well-defined leaflets showing sufficient coaptation. There were no signs of pressure damage, leaflet rupture, or thrombus formation detectable. Also See Online Videos 1, 2, 3A, 3B, and 3C.